Acute progressive and extensive metastatic calcifications in a nephrotic patient following chronic hemodialysis.
We report on a 46-year-old female patient with a 5-year history of refractory nephrotic syndrome who rapidly developed extensive metastatic calcifications in lung, bone, blood vessels, skin, uterus and other soft tissues following maintenance hemodialysis. She was admitted for controlling anasarca. On admission, she suffered from severe nephrotic syndrome and chronic renal failure, showing 1.3 g/dl of serum albumin and 4.6 mg/dl of serum creatinine. She received bicarbonate dialysis combined with extracorporeal ultrafiltration to control anasarca. Following hemodialysis, she was treated with alfacalcidol and an increasing dose of calcium carbonate. Although anasarca was controlled, her nephrotic state remained unchanged. After 3 months of dialysis, roentgenograms of the body disclosed multiple metastatic calcifications. At this time, though the calcium-phosphorous product in serum was almost normal, the free calcium index was confirmed to have been high for 4 weeks. We considered that administration of calcium carbonate and alfacalcidol as well as an influx of free calcium from a dialysate resulted in increased serum ionized calcium which may be unable to be bound to serum protein because of lack of total protein, leading to ectopic deposition of calcium and phosphate. Our findings suggested that intensive care is needed to prevent metastatic calcification when uremic patients with severe nephrosis are treated with bicarbonate hemodialysis.
Uchida
M
M
Department of Internal Medicine, Saga Medical School, Japan.
Sakemi
T
T
Ikeda
Y
Y
Maeda
T
T
D000208:Acute Disease; D001639:Bicarbonates / Q000009:adverse effects; D002114:Calcinosis / Q000209:etiology* / Q000473:pathology; D015314:Dialysis Solutions / Q000009:adverse effects; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000628:therapy*; D006435:Renal Dialysis / Q000009:adverse effects*; D012871:Skin Diseases / Q000209:etiology / Q000473:pathology; D013997:Time Factors; D014591:Uterine Diseases / Q000209:etiology / Q000473:pathology
D001639:Bicarbonates; D015314:Dialysis Solutions